Literature DB >> 9259272

Cloning, mRNA distribution and chromosomal localisation of the gene for glial cell line-derived neurotrophic factor receptor beta, a homologue to GDNFR-alpha.

P Suvanto1, K Wartiovaara, M Lindahl, U Arumae, M Moshnyakov, N Horelli-Kuitunen, M S Airaksinen, A Palotie, H Sariola, M Saarma.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) is a potent survival factor for central dopaminergic neurons, motor neurons and several other populations of neurons in the central and peripheral nervous system. GDNF and its receptor complex of c-RET tyrosine kinase and a glycosyl-phosphatidylinositol linked protein GDNFR-alpha are of great interest due to their potential use in the therapy of Parkinson's and motoneuron diseases. We have cloned the human and rat cDNA sequences of GDNFR-beta, a new gene encoding for a 464 amino acid long homologue of GDNFR-alpha, and assign the locus of this new gene to human chromosome 8p21-22 and mouse chromosome 14D3-E1. Similarly to GDNFR-alpha, GDNFR-beta mediates GDNF-induced Ret autophosphorylation in transfected cells. By northern hybridisation we show that the transcript level of human GDNFR-beta mRNA is high in the adult brain, intestine and placenta and in fetal brain, lung and kidney. Studied by in situ hybridisation, GDNFR-beta mRNA shows in E17 rat embryo different distribution to that of GDNFR-alpha mRNA, especially, in adrenal gland, kidney and gut. In the developing nervous system, GDNFR-beta mRNA expression is restricted to certain neuronal populations, while GDNFR-alpha mRNA is widely expressed also in non-neuronal cells. The distinct tissue distribution of GDNFR-beta mRNA and its ability to mediate GDNF signal in transfected cells suggest a role in signal transduction of GDNF and, possibly, related neurotrophic factors in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259272     DOI: 10.1093/hmg/6.8.1267

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

1.  New roles for glial cell line-derived neurotrophic factor and neurturin: involvement in hair cycle control.

Authors:  N V Botchkareva; V A Botchkarev; P Welker; M Airaksinen; W Roth; P Suvanto; S Müller-Röver; I M Hadshiew; C Peters; R Paus
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Investigation of germline GFR alpha-1 mutations in Hirschsprung disease.

Authors:  S M Myers; R Salomon; A Goessling; A Pelet; C Eng; A von Deimling; S Lyonnet; L M Mulligan
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

3.  Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific.

Authors:  M L Leitner; D C Molliver; P A Osborne; R Vejsada; J P Golden; P A Lampe; A C Kato; J Milbrandt; E M Johnson
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

4.  GDNF: a novel factor with therapeutic potential for neurodegenerative disorders.

Authors:  K M Walton
Journal:  Mol Neurobiol       Date:  1999-02       Impact factor: 5.590

5.  Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-beta as cofactor in vivo.

Authors:  A Schober; R Hertel; U Arumäe; L Farkas; J Jaszai; K Krieglstein; M Saarma; K Unsicker
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

6.  Ret and Etv4 Promote Directed Movements of Progenitor Cells during Renal Branching Morphogenesis.

Authors:  Paul Riccio; Cristina Cebrian; Hui Zong; Simon Hippenmeyer; Frank Costantini
Journal:  PLoS Biol       Date:  2016-02-19       Impact factor: 8.029

7.  High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

Authors:  Susanna L Cooke; Jessica C M Pole; Suet-Feung Chin; Ian O Ellis; Carlos Caldas; Paul A W Edwards
Journal:  BMC Cancer       Date:  2008-10-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.